Background

Long COVID is characterized by persistent, multisystem symptoms with no approved pharmacologic treatments. This retrospective study evaluates the off-label use of low-dose aripiprazole (LDA) in a specialized Long COVID clinic.

Methods

  • Population: 50 adult patients
  • Dose range: 0.1–2.0 mg daily
  • Outcome measures:
  • Functional Status Scale (FSS)
  • Composite symptom severity score

Results

Functional Outcomes

Outcome Change
Functional Status Scale Significant improvement (p=0.0149)
Composite Symptom Score p < 0.001
Clinically meaningful improvement 22% of patients

Functional transitions

Interpretation

While limited by retrospective design, the findings suggest that LDA may modulate neuroinflammatory pathways relevant to Long COVID symptomatology. Controlled trials are warranted.

Clinical Relevance

This study highlights:
- The value of real-world EHR analyses
- Rapid hypothesis generation for repurposed therapies
- The importance of functional, patient-centered endpoints

Disclosures

This study was conducted independently of the funding source.